Navigation Links
Profusa, Inc. Announces $13.2 Million Series B to Support Development of Internal Biosensors for Continuous Monitoring of Body Chemistry
Date:12/16/2015

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2015 /PRNewswire/ -- Profusa, Inc., based here, today announced it secured $13.2 million in Series B financing to support the development and com­mercialization of its internal biosensor technology for long-term, continuous monitoring of body chemistry for improving personal health and managing disease. 3E Bioventures, a Beijing-based venture capital firm, led the round with Asset Management Ventures, Qihoo 360, and other Series A investors participating in the funding. All told, including non-dilutive grants, the new financing brings to the privately held company more than $30 million in funding since its founding in 2009. Other financial details were not disclosed.

Profusa also said it appointed to its board of directors Joan Braddi, Vice President of Global Product Partnerships at Google, Inc., a subsidiary of Alphabet Inc. Karen Liu, Ph.D., Managing Partner of 3E Bioventures, also joined Profusa's board in conjunction with her firm's investment in the Series B round.

"This round, coupled with prominent board appointments from the biotechnology and IT sectors, provide Profusa with the additional funding and market experience to help ensure our success," said Ben Hwang, Ph.D., Profusa's chairman and CEO.

As Google's 15th employee for as many years, Braddi is responsible for building and man­aging content and distribution partnerships that get Google's products into the hands of users around the world. Dr. Liu heads 3E Bioventures' investing in the U.S. and China, and is active in creating cross-border opportunities in healthcare.

Profusa, Inc. is leading the development of a new generation of biologically integrated sensors that empowers an individual with the ability to continuously monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Overcoming the body's response to foreign material, the company's technology enables the development of minute bioengineered sensors that become one with the body to detect and transmit clinical-grade data for personal and medical use. The company's first product, the Lumee Oxygen Sensing System™, is slated to be available in Europe in early 2016 for the measurement of tissue-oxygen perfusion in the clinical management of chronic wounds.

Logo - http://photos.prnewswire.com/prnh/20151215/296354LOGO

 


'/>"/>
SOURCE Profusa, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
2. Annual Conference about Technology Solutions for People with Disabilities Announces Program
3. Probiotic Action Announces Probiotics Lead the Digestive Health Market
4. Verenium Announces Preliminary Financial Results For Fiscal 2012
5. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
6. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
7. EAG Announces New General Manager of Release-To-Production (RTP) Division
8. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
9. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
10. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
11. 3D Biomatrix Announces Stipend to Present at Spring 2013 Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... New York, NY (PRWEB) , ... October 12, ... ... York Academy of Sciences today announced the three Winners and six Finalists of ... Awards are given annually by the Blavatnik Family Foundation and administered by the ...
(Date:10/12/2017)... FL (PRWEB) , ... October ... ... (RPS®) today announces publication of a United States multicenter, prospective clinical study ... use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):